Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2025 07:14 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.
October 09, 2025 09:00 ET | Source: Bay Area Lyme Foundation

Journal of Clinical Microbiology Studies Demonstrate Two Investigational Diagnostics Outperform Current Tests in Detecting Early Lyme Disease

PORTOLA VALLEY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, the leading nonprofit funder of Lyme disease research in the US, today announced results from two independent...
September 04, 2025 11:00 ET | Source: Bay Area Lyme Foundation

Bay Area Lyme Foundation Launches Bay Area Lyme Ventures as First Impact Investment Fund to Support Entrepreneurs and Companies Advancing Lyme Disease Solutions

PORTOLA VALLEY, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced the launch of Bay Area Lyme Ventures (Lyme...
July 10, 2025 03:00 ET | Source: Bay Area Lyme Foundation

New Bay Area Lyme Foundation Study Reports That Only One-Third of Early Lyme Patients with On-Going Symptoms Followed up with their Healthcare Providers

The new research, published in Frontiers in Medicine, points to the need for greater follow-up from medical professionals to address potential treatment failures. PORTOLA VALLEY, Calif., July 10,...
June 18, 2025 11:00 ET | Source: Bay Area Lyme Foundation

Bay Area Lyme Foundation Announces New Executive Director Josh Wein

PORTOLA VALLEY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, has hired Josh Wein to serve as its new executive director,...
June 12, 2025 11:05 ET | Source: Bay Area Lyme Foundation

Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test

PORTOLA VALLEY, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, has given its 2025 Emerging Leader Award (ELA) to Chao Wang,...
April 23, 2025 14:00 ET | Source: Bay Area Lyme Foundation

Science Translational Medicine Study Funded by the Bay Area Lyme Foundation Identifies FDA-approved Piperacillin as More Effective, Targeted Treatment for Lyme Disease

PORTOLA VALLEY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces two pre-clinical studies published in the...
April 22, 2025 08:44 ET | Source: Sixty Degrees Pharmaceuticals

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
April 08, 2025 08:31 ET | Source: Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.
January 28, 2025 08:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.